Plague Pipeline

Adjuvant-free dual anthrax / plague vaccine

A US academic particle. Bacteriophage T4 decorated with an F1–V fusion and anthrax protective antigen, designed to work without a separate adjuvant. Pneumonic mouse model, 2018. A dual anthrax and plague concept, still preclinical, with no named public company.

Stage chart

Preclinical

Phase 1

Phase 2

Phase 3

Licensed

Preclinical · pneumonic. Phase 3 is empty here, as it is for every programme in the set.

Years on the record

A mark at 2018. Labelled “2018” on the briefing. Not a forecast.

Analyst card

Challenge: Pneumonic mouse model, 2018.
F1-negative strains: Not reported. The particle displays an F1–V fusion.
Adjuvant: None added.
Route: Not stated.
Stability: Formulation and cold-chain requirement are not stated.
Time to protection: Not reported. No time-to-protection figure is in the briefing.
Other threats: Plague F1–V and anthrax protective antigen on bacteriophage T4.
Survival figure: No survival percentage in the briefing.
Animal Rule: Mouse data. Not an Animal Rule file.

Pipeline record

Particle: Bacteriophage T4.
What is displayed: An F1–V fusion and anthrax protective antigen.
Adjuvant: None added. The particle is meant to be the delivery.
Model: Pneumonic mice. 2018. US academic. A dual anthrax and plague concept, still preclinical.

News

Checking today’s headlines.

Latest intel

Checking Europe PMC.

PubMed

Checking today’s index.

Platform: Nanoparticle
Antigens displayed on a particle — a bacteriophage, or a degradable polymer — to change how the immune system meets them.
Who is paying: US — academic
Country: United States
What was tested: Pneumonic
Stage: Preclinical · pneumonic
Date: 2018
Antigens named: F1V / LcrVWith anthrax